HK1211239A1 - Treatment regimens - Google Patents
Treatment regimensInfo
- Publication number
- HK1211239A1 HK1211239A1 HK15112183.5A HK15112183A HK1211239A1 HK 1211239 A1 HK1211239 A1 HK 1211239A1 HK 15112183 A HK15112183 A HK 15112183A HK 1211239 A1 HK1211239 A1 HK 1211239A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment regimens
- regimens
- treatment
- Prior art date
Links
- 238000011269 treatment regimen Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261679999P | 2012-08-06 | 2012-08-06 | |
PCT/US2013/053843 WO2014025814A1 (fr) | 2012-08-06 | 2013-08-06 | Régimes de traitement |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1211239A1 true HK1211239A1 (en) | 2016-05-20 |
Family
ID=50068530
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112183.5A HK1211239A1 (en) | 2012-08-06 | 2015-12-10 | Treatment regimens |
HK16102368.2A HK1214505A1 (zh) | 2012-08-06 | 2016-03-01 | 治療方案 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16102368.2A HK1214505A1 (zh) | 2012-08-06 | 2016-03-01 | 治療方案 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9517254B2 (fr) |
EP (1) | EP2879680A4 (fr) |
JP (2) | JP2015524474A (fr) |
KR (3) | KR20230136142A (fr) |
CN (2) | CN104884060A (fr) |
AU (2) | AU2013299725A1 (fr) |
BR (1) | BR112015002687A2 (fr) |
CA (1) | CA2881388A1 (fr) |
EA (1) | EA201590349A1 (fr) |
HK (2) | HK1211239A1 (fr) |
IL (1) | IL237150B (fr) |
MX (1) | MX2015001695A (fr) |
SG (3) | SG10201709967YA (fr) |
WO (1) | WO2014025814A1 (fr) |
ZA (1) | ZA201501562B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2933921A1 (fr) * | 2016-06-17 | 2017-12-17 | S1 Biopharma, Inc. | Methodes de traitement des femmes souffrant de baisse du desir sexuel au moyen d'un traitement combinant le bupropion et la trazodone |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
DE4321965A1 (de) | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
JP2002322085A (ja) | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | 知的機能障害治療剤 |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
WO2004030524A2 (fr) * | 2002-10-03 | 2004-04-15 | Pr Pharmaceuticals | Traitement de l'autisme et de troubles similaires |
JP2007525442A (ja) * | 2003-03-05 | 2007-09-06 | ピーアール ファーマシューティカルズ,インコーポレイテッド | オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法 |
CN1946404A (zh) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
KR20070014184A (ko) * | 2004-04-22 | 2007-01-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 성기능 장애 치료용 신규 약제학적 조성물 ⅱ |
US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
US20060122127A1 (en) | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
US20060211685A1 (en) | 2005-03-04 | 2006-09-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
US9023793B2 (en) * | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
CA2667909A1 (fr) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | Traitement des troubles pervasifs du developpement |
WO2008075162A2 (fr) * | 2006-12-15 | 2008-06-26 | Pfizer Limited | Composés pour le traitement d'un dysfonctionnement sexuel |
WO2009016488A2 (fr) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprenant des antidépresseurs tétracycliques pour le traitement d'un cancer et procédés apparentés |
EP2331097A4 (fr) * | 2008-08-21 | 2011-12-28 | Richter Gedeon Nyrt | Procédés de traitement de troubles du système nerveux central (cns) |
ES2731228T3 (es) * | 2009-01-20 | 2019-11-14 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico |
AU2011252764B2 (en) | 2010-05-14 | 2012-12-13 | Charlotte L. Keating | Neuropsychopharmacological treatment regimes for treating psychological disorders |
WO2011146726A1 (fr) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Méthodes et formulations pour le traitement par l'oxytocine de troubles liés à l'utilisation de substances toxiques, de troubles psychiatriques et autres troubles |
US9585935B2 (en) | 2010-07-30 | 2017-03-07 | The Regents Of The University Of California | Intranasal oxytocin treatment to improve schizophrenia |
CN103635190B (zh) | 2011-04-04 | 2016-09-07 | S1生物药有限公司 | 治疗方案 |
-
2013
- 2013-08-06 CA CA2881388A patent/CA2881388A1/fr not_active Abandoned
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/ko not_active Application Discontinuation
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/fr active Application Filing
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/ko not_active Application Discontinuation
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/zh active Pending
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/ja not_active Ceased
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/ko not_active Application Discontinuation
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/zh active Pending
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/pt not_active IP Right Cessation
- 2013-08-06 EA EA201590349A patent/EA201590349A1/ru unknown
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/es unknown
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/fr not_active Withdrawn
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
- 2015-12-10 HK HK15112183.5A patent/HK1211239A1/xx unknown
-
2016
- 2016-03-01 HK HK16102368.2A patent/HK1214505A1/zh unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/ja active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20200128437A (ko) | 2020-11-12 |
BR112015002687A2 (pt) | 2019-12-17 |
CA2881388A1 (fr) | 2014-02-13 |
SG10201709967YA (en) | 2018-01-30 |
HK1214505A1 (zh) | 2016-07-29 |
US20150150946A1 (en) | 2015-06-04 |
MX2015001695A (es) | 2015-09-28 |
SG11201500919PA (en) | 2015-04-29 |
CN106924259A (zh) | 2017-07-07 |
EA201590349A1 (ru) | 2015-07-30 |
IL237150A0 (en) | 2015-04-30 |
AU2013299725A1 (en) | 2015-03-26 |
EP2879680A4 (fr) | 2016-06-01 |
WO2014025814A1 (fr) | 2014-02-13 |
EP2879680A1 (fr) | 2015-06-10 |
US9517254B2 (en) | 2016-12-13 |
IL237150B (en) | 2018-07-31 |
SG10201908587PA (en) | 2019-10-30 |
JP2015524474A (ja) | 2015-08-24 |
KR20150063039A (ko) | 2015-06-08 |
ZA201501562B (en) | 2017-11-29 |
JP2018150357A (ja) | 2018-09-27 |
AU2018205121A1 (en) | 2018-07-26 |
CN104884060A (zh) | 2015-09-02 |
KR20230136142A (ko) | 2023-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254716B (en) | Zinc-lysine conjugate | |
HK1211475A1 (en) | Combination therapy | |
GB201212513D0 (en) | Therapeutic agents | |
EP2906208A4 (fr) | Traitement thérapeutique | |
GB201217439D0 (en) | Combination therapy | |
PT2838854T (pt) | Tratamento de água | |
EP2932922A4 (fr) | Outil de traitement | |
GB201217704D0 (en) | Therapeutic agents | |
GB201207305D0 (en) | Therapy | |
HK1210426A1 (en) | Combination therapy | |
PL2653448T3 (pl) | Uzdatnianie wody | |
ZA201307760B (en) | Treatment regimens | |
EP2904981A4 (fr) | Outil de traitement | |
HK1214505A1 (zh) | 治療方案 | |
ZA201409343B (en) | Water treatment | |
EP2804853A4 (fr) | Utilisations thérapeutiques | |
EP2704731A4 (fr) | Traitement d'origine aviaire | |
GB201211135D0 (en) | Treatment | |
GB201208690D0 (en) | Treatment | |
GB201212604D0 (en) | New treatment | |
GB201211543D0 (en) | Combination therapy | |
GB201221326D0 (en) | Novel treatments | |
GB201215607D0 (en) | Water treatment | |
GB201223021D0 (en) | Therapeutic agents | |
GB201212512D0 (en) | Therapeutic agents |